The	O
sensitivity	O
and	O
specifity	O
of	O
DR	B:C0041365
-	I:C0041365
70	I:C0041365
immunoassay	O
as	O
a	O
tumor	O
marker	I:C0041365
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
Lung	O
cancer	I:C0242379
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR	O
-	I:C0041365
70	I:C0041365
immunoassay	B:C0020980
as	O
a	O
tumor	O
marker	I:C0041365
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
Lung	O
cancer	I:C0242379
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR	O
-	I:C0041365
70	I:C0041365
immunoassay	O
as	O
a	O
tumor	B:C0041365
marker	I:C0041365
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
Lung	O
cancer	I:C0242379
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR	O
-	I:C0041365
70	I:C0041365
immunoassay	O
as	O
a	O
tumor	O
marker	I:C0041365
for	O
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
Lung	O
cancer	I:C0242379
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR	O
-	I:C0041365
70	I:C0041365
immunoassay	O
as	O
a	O
tumor	O
marker	I:C0041365
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
Lung	B:C0242379
cancer	I:C0242379
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

Patients	O
with	O
lung	B:C0242379
cancer	I:C0242379
are	O
usually	O
diagnosed	O
at	O
advanced	O
or	O
locally	O
advanced	I:C0005898
stage	I:C0005898
,	O
for	O
this	O
reason	O
early	O
diagnosis	I:C0596473
of	O
lung	O
cancer	I:C0242379
is	O
very	O
important	O
.	O

Patients	O
with	O
lung	O
cancer	I:C0242379
are	O
usually	O
diagnosed	B:C0430022
at	O
advanced	O
or	O
locally	O
advanced	I:C0005898
stage	I:C0005898
,	O
for	O
this	O
reason	O
early	O
diagnosis	I:C0596473
of	O
lung	O
cancer	I:C0242379
is	O
very	O
important	O
.	O

Patients	O
with	O
lung	O
cancer	I:C0242379
are	O
usually	O
diagnosed	O
at	O
advanced	B:C0005898
or	O
locally	O
advanced	I:C0005898
stage	I:C0005898
,	O
for	O
this	O
reason	O
early	O
diagnosis	I:C0596473
of	O
lung	O
cancer	I:C0242379
is	O
very	O
important	O
.	O

Patients	O
with	O
lung	O
cancer	I:C0242379
are	O
usually	O
diagnosed	O
at	O
advanced	O
or	O
locally	B:C0005898
advanced	I:C0005898
stage	I:C0005898
,	O
for	O
this	O
reason	O
early	O
diagnosis	I:C0596473
of	O
lung	O
cancer	I:C0242379
is	O
very	O
important	O
.	O

Patients	O
with	O
lung	O
cancer	I:C0242379
are	O
usually	O
diagnosed	O
at	O
advanced	O
or	O
locally	O
advanced	I:C0005898
stage	I:C0005898
,	O
for	O
this	O
reason	O
early	B:C0596473
diagnosis	I:C0596473
of	O
lung	O
cancer	I:C0242379
is	O
very	O
important	O
.	O

Patients	O
with	O
lung	O
cancer	I:C0242379
are	O
usually	O
diagnosed	O
at	O
advanced	O
or	O
locally	O
advanced	I:C0005898
stage	I:C0005898
,	O
for	O
this	O
reason	O
early	O
diagnosis	I:C0596473
of	O
lung	B:C0242379
cancer	I:C0242379
is	O
very	O
important	O
.	O

For	O
early	B:C0596473
detection	I:C0596473
of	O
lung	O
cancer	I:C0242379
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	O
-	I:C0040405
dose	I:C0040405
computed	I:C0040405
tomography	I:C0040405
or	O
tumor	O
biomarkers	I:C0041366
.	O

For	O
early	O
detection	I:C0596473
of	O
lung	B:C0242379
cancer	I:C0242379
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	O
-	I:C0040405
dose	I:C0040405
computed	I:C0040405
tomography	I:C0040405
or	O
tumor	O
biomarkers	I:C0041366
.	O

For	O
early	O
detection	I:C0596473
of	O
lung	O
cancer	I:C0242379
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	B:C0040405
-	I:C0040405
dose	I:C0040405
computed	I:C0040405
tomography	I:C0040405
or	O
tumor	O
biomarkers	I:C0041366
.	O

For	O
early	O
detection	I:C0596473
of	O
lung	O
cancer	I:C0242379
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	O
-	I:C0040405
dose	I:C0040405
computed	I:C0040405
tomography	I:C0040405
or	O
tumor	B:C0041366
biomarkers	I:C0041366
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B:C0220825
DR	O
-	I:C0041365
70	I:C0041365
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	I:C0041365
in	O
detection	O
of	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancers	I:C0007131
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR	B:C0041365
-	I:C0041365
70	I:C0041365
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	I:C0041365
in	O
detection	O
of	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancers	I:C0007131
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR	O
-	I:C0041365
70	I:C0041365
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	B:C0041365
marker	I:C0041365
in	O
detection	O
of	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancers	I:C0007131
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR	O
-	I:C0041365
70	I:C0041365
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	I:C0041365
in	O
detection	B:C1511790
of	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancers	I:C0007131
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR	O
-	I:C0041365
70	I:C0041365
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	I:C0041365
in	O
detection	O
of	O
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancers	I:C0007131
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	B:C1550100
samples	I:C1550100
from	O
88	O
non	O
lung	I:C0006826
cancer	I:C0006826
patients	O
,	O
86	O
patients	O
with	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disesase	I:C0024117
were	O
obtained	O
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	O
samples	I:C1550100
from	O
88	O
non	B:C0006826
lung	I:C0006826
cancer	I:C0006826
patients	O
,	O
86	O
patients	O
with	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disesase	I:C0024117
were	O
obtained	O
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	O
samples	I:C1550100
from	O
88	O
non	O
lung	I:C0006826
cancer	I:C0006826
patients	O
,	O
86	O
patients	O
with	O
chronic	B:C0024117
obstructive	I:C0024117
pulmonary	I:C0024117
disesase	I:C0024117
were	O
obtained	O
.	O

Blood	B:C0178913
samples	I:C0178913
from	O
each	O
participant	O
were	O
analyzed	O
for	O
DR	O
-	I:C0041365
70	I:C0041365
level	O
.	O

Blood	O
samples	I:C0178913
from	O
each	O
participant	B:C0679646
were	O
analyzed	O
for	O
DR	O
-	I:C0041365
70	I:C0041365
level	O
.	O

Blood	O
samples	I:C0178913
from	O
each	O
participant	O
were	O
analyzed	B:C0936012
for	O
DR	O
-	I:C0041365
70	I:C0041365
level	O
.	O

Blood	O
samples	I:C0178913
from	O
each	O
participant	O
were	O
analyzed	O
for	O
DR	B:C0041365
-	I:C0041365
70	I:C0041365
level	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	B:C2603343
(	O
152	O
male	O
,	O
22	O
female	O
)	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	O
(	O
152	O
male	B:C0025266
,	O
22	O
female	O
)	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	O
(	O
152	O
male	O
,	O
22	O
female	B:C0043210
)	O
.	O

Histopathologically	O
47(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	B:C0430022
with	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	O
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	O
-small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Histopathologically	O
47(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	O
with	O
squamous	B:C0149782
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	O
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	O
-small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Histopathologically	O
47(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	O
with	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	B:C0001418
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	O
-small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Histopathologically	O
47(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	O
with	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	O
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	B:C0007131
-small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
mean	B:C0041365
serum	I:C0041365
DR	I:C0041365
-	I:C0041365
70	I:C0041365
levels	O
in	O
lung	O
cancer	I:C0242379
patients	O
(	O
2.43	O
±	O
1.82	O
µ	O
g/mL	O
)	O
was	O
significantly	O
higher	I:C0243095
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/	O
mL	O
)	O
(	O
p<	O
0.01	O
)	O
.	O

The	O
mean	O
serum	I:C0041365
DR	I:C0041365
-	I:C0041365
70	I:C0041365
levels	O
in	O
lung	B:C0242379
cancer	I:C0242379
patients	O
(	O
2.43	O
±	O
1.82	O
µ	O
g/mL	O
)	O
was	O
significantly	O
higher	I:C0243095
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/	O
mL	O
)	O
(	O
p<	O
0.01	O
)	O
.	O

The	O
mean	O
serum	I:C0041365
DR	I:C0041365
-	I:C0041365
70	I:C0041365
levels	O
in	O
lung	O
cancer	I:C0242379
patients	O
(	O
2.43	O
±	O
1.82	O
µ	O
g/mL	O
)	O
was	O
significantly	B:C0243095
higher	I:C0243095
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/	O
mL	O
)	O
(	O
p<	O
0.01	O
)	O
.	O

The	O
mean	O
serum	I:C0041365
DR	I:C0041365
-	I:C0041365
70	I:C0041365
levels	O
in	O
lung	O
cancer	I:C0242379
patients	O
(	O
2.43	O
±	O
1.82	O
µ	O
g/mL	O
)	O
was	O
significantly	O
higher	I:C0243095
compared	O
to	O
the	O
86	O
non-cancerous	B:C0243095
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/	O
mL	O
)	O
(	O
p<	O
0.01	O
)	O
.	O

The	O
mean	O
serum	I:C0041365
DR	I:C0041365
-	I:C0041365
70	I:C0041365
levels	O
in	O
lung	O
cancer	I:C0242379
patients	O
(	O
2.43	O
±	O
1.82	O
µ	O
g/mL	O
)	O
was	O
significantly	O
higher	I:C0243095
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	B:C2349001
(	O
1.15	O
±	O
0.70	O
µg/	O
mL	O
)	O
(	O
p<	O
0.01	O
)	O
.	O

DR	B:C0041365
-	I:C0041365
70	I:C0041365
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54.5	O
and	O
83.7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1.98	O
µg/	O
mL	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B:C0012634
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR	O
-	I:C0041365
70	I:C0041365
level	O
is	O
1.98	O
µg	O
/	O
mL	O
and	O
higher	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	O
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR	B:C0041365
-	I:C0041365
70	I:C0041365
level	O
is	O
1.98	O
µg	O
/	O
mL	O
and	O
higher	O
.	O

DR	B:C0041365
-	I:C0041365
70	I:C0041365
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	I:C0163275
products	I:C0163275
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	I:C0332167
lung	O
cancer	I:C0242379
patients	O
.	O

DR	O
-	I:C0041365
70	I:C0041365
,	O
a	O
marker	B:C0041365
used	O
to	O
measure	O
fibrin	O
degradation	I:C0163275
products	I:C0163275
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	I:C0332167
lung	O
cancer	I:C0242379
patients	O
.	O

DR	O
-	I:C0041365
70	I:C0041365
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	B:C0163275
degradation	I:C0163275
products	I:C0163275
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	I:C0332167
lung	O
cancer	I:C0242379
patients	O
.	O

DR	O
-	I:C0041365
70	I:C0041365
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	I:C0163275
products	I:C0163275
,	O
generated	O
by	O
all	O
major	O
cancers	B:C0006826
,	O
may	O
helps	O
to	O
find	O
high	O
risk	I:C0332167
lung	O
cancer	I:C0242379
patients	O
.	O

DR	O
-	I:C0041365
70	I:C0041365
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	I:C0163275
products	I:C0163275
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	B:C0332167
risk	I:C0332167
lung	O
cancer	I:C0242379
patients	O
.	O

DR	O
-	I:C0041365
70	I:C0041365
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	I:C0163275
products	I:C0163275
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	I:C0332167
lung	B:C0242379
cancer	I:C0242379
patients	O
.	O

